Fabian Byvald | Karolinska Institutet

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Journal article: ONCOIMMUNOLOGY. 2026;15(1):2641261
Polarization of tumor-infiltrating macrophages predicts complete response to neoadjuvant treatment in patients with rectal cancer
Alkan A; Byvald F; Gronkvist R; Danielsson G; Cumming J; Falk P; Angenete E; Yrlid U
Article: DIABETOLOGIA. 2025;68(10):2277-2289
Frequent longitudinal blood microsampling and proteome monitoring identify disease markers and enable timely intervention in a mouse model of type 1 diabetes
Parajuli A; Bendes A; Byvald F; Stone VM; Ringqvist EE; Butrym M; Angelis E; Kipper S; Bauer S; Roxhed N; Schwenk JM; Flodstrom-Tullberg M
Article: ANTIVIRAL RESEARCH. 2024;231:106021
Vemurafenib inhibits the replication of diabetogenic enteroviruses in intestinal epithelial and pancreatic beta cells
Butrym M; Byvald F; Blanter M; Ringqvist EE; Vasylovska S; Marjomaki V; Lau J; Stone VM; Flodstrom-Tullberg M
Article: ONCOIMMUNOLOGY. 2023;12(1):2209473
A type I interferon footprint in pre-operative biopsies is an independent biomarker that in combination with CD8⁺ T cell quantification can improve the prediction of response to neoadjuvant treatment of rectal adenocarcinoma
Rezapour A; Rydbeck D; Byvald F; Tasselius V; Danielsson G; Angenete E; Yrlid U
Article: CANCERS. 2022;14(12):2882
A Fraction of CD8+T Cells from Colorectal Liver Metastases Preferentially Repopulate Autologous Patient-Derived Xenograft Tumors as Tissue-Resident Memory T Cells
Liang F; Nilsson LM; Byvald F; Rezapour A; Taflin H; Nilsson JA; Yrlid U

Alla övriga publikationer

Doctoral thesis: 2026
Type 1 diabetes : immunomodulatory cytokines, predictive biomarkers and antiviral therapies
Byvald F

Anställningar

Doktorand, Medicin, Huddinge, Karolinska Institutet, 2022-2026

Examina och utbildning

Medicine Doktorsexamen, Institutionen för medicin, Huddinge, Karolinska Institutet, 2026

Nyheter från KI

Kalenderhändelser från KI